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Background and objectives: Cancer stem cells (CSCs) have been implicated in
tumor initiation, recurrence, metastatic spread and poor survival in multiple tumor
types, breast cancers included. CSCs selectively overexpress key mitochondrial-related
proteins and inhibition of mitochondrial function may represent a new potential approach
for the eradication of CSCs. Because mitochondria evolved from bacteria, many classes
of FDA-approved antibiotics, including doxycycline, actually target mitochondria. Our
clinical pilot study aimed to determine whether short-term pre-operative treatment with
oral doxycycline results in reduction of CSCs in early breast cancer patients.
Methods: Doxycycline was administered orally for 14 days before surgery for a daily
dose of 200mg. Immuno-histochemical analysis of formalin-fixed paraffin-embedded
(FFPE) samples from 15 patients, of which 9 were treated with doxycycline and 6 were
controls (no treatment), was performed with known biomarkers of “stemness” (CD44,
ALDH1), mitochondria (TOMM20), cell proliferation (Ki67, p27), apoptosis (cleaved
caspase-3), and neo-angiogenesis (CD31). For each patient, the analysis was performed
both on pre-operative specimens (core-biopsies) and surgical specimens. Changes from
baseline to post-treatment were assessed with MedCalc 12 (unpaired t-test) and ANOVA.
Results: Post-doxycycline tumor samples demonstrated a statistically significant
decrease in the stemness marker CD44 (p-value < 0.005), when compared
to pre-doxycycline tumor samples. More specifically, CD44 levels were reduced
between 17.65 and 66.67%, in 8 out of 9 patients treated with doxycycline.
In contrast, only one patient showed a rise in CD44, by 15%. Overall, this
represents a positive response rate of nearly 90%. Similar results were also obtained
with ALDH1, another marker of stemness. In contrast, markers of mitochondria,
proliferation, apoptosis, and neo-angiogenesis, were all similar between the two groups.
Scatena et al. Doxycycline Effectively Reduces CSCs
Conclusions: Quantitative decreases in CD44 and ALDH1 expression are consistent
with pre-clinical experiments and suggest that doxycycline can selectively eradicate
CSCs in breast cancer patients in vivo. Future studies (with larger numbers of patients)
will be conducted to validate these promising pilot studies.
Keywords: doxycycline, mitochondria, cancer stem cells, translational study, mitochondrial biogenesis
INTRODUCTION
Tumor-initiating cells (TICs) share many functional
characteristics with normal stem cells and are important
drivers of tumor initiation and cancer progression (1–7). As
such, new therapies for targeting TICs [a.k.a., cancer stem cells
(CSCs)] could be used for cancer prevention. Interestingly,
circulating tumor cells (CTCs) can also functionally behave as
initiators of tumor formation.
Because of their resistance to conventional anti-cancer
treatments (i.e., chemo-therapy and radio-therapy), CSCs are
also thought to underpin the cellular and molecular basis of
tumor recurrence, distant metastasis and ultimately treatment
failure, inmost cancer types (1–6). Thus, new treatment strategies
are urgently needed to help remedy this unmet clinical need
(1–4).
One simplistic idea is to identify novel therapeutic targets that
are relatively unique to CSCs, which can be then be inhibited with
FDA-approved drugs that show few side effects and have excellent
safety profiles (1–3). We recently used this promising approach
to identify mitochondria in CSCs as a conserved therapeutic
target (7). In this context, the antibiotic doxycycline emerged
as an excellent candidate for drug repurposing (8, 9). In 1967,
Doxycycline was first approved by the FDA, more than 50 years
ago. It shows minimal side effects and is currently used world-
wide as a broad-spectrum antibiotic, mainly for the treatment
of acne and acne rosacea. Doxycycline has excellent pharmaco-
kinetics, with very good oral absorption (∼100%) and a long
serum half-life (18–22 h), at the standard dose of 200mg per day.
Doxycycline functionally behaves as a non-toxic inhibitor
of mitochondrial biogenesis, because of the evolutionarily
conserved similarities between bacterial ribosomes and
mitochondrial ribosomes (10–12). Therefore, this “manageable
side-effect” of doxycycline could be repurposed as a “therapeutic
effect,” to target and inhibit mitochondrial biogenesis in CSCs
(13, 14).
Previously, doxycycline has been used clinically to target
cancer-associated infections, with promising results, leading to a
complete pathological response (CPR) or “remission” in patients
with MALT lymphoma (15, 16). Interestingly, this CPR did
not correlate with the presence of micro-organisms, possibly
suggesting that doxycycline might be acting on the tumor cells
themselves.
In 2015, the Sotgia/Lisanti laboratory first demonstrated
that doxycycline treatment was sufficient to successfully halt
the propagation of CSCs in vitro (13, 14). For this purpose,
we tested 12 different human tumor cell lines, representing
eight different cancer types, such as DCIS, breast [ER(+) and
ER(-)], lung, ovarian, pancreatic, and prostate carcinomas, as
well as glioblastoma (GBM) and melanoma (13). Remarkably,
doxycycline inhibited CSC propagation across this entire panel
of diverse cell lines (13).
Further mechanistic studies, using luciferase based assays
in MCF7 cells (a human breast cancer cell line) revealed
that doxycycline treatment effectively inhibits CSC signaling,
across multiple pathways, including Wnt, Notch, Hedgehog and
STAT1/3-signaling (14). Therefore, doxycycline is an excellent
candidate for drug repurposing, in clinical pilot studies aimed
at validating its ability to target CSCs in cancer patients.
As such, here we evaluated the ability of doxycycline to
target CSCs in breast cancer patients in vivo, using well-
established CSC markers (CD44 and ALDH1) as a read-
out.
The ability of doxycycline to target breast CSCs in vitro has
already been confirmed independently (17, 18) and extended to
several other classes of antibiotics and mitochondrial OXPHOS
inhibitors (19–24). Consistent with these findings, mitochondrial
mass is increased in CSCs (25, 26) and high expression
levels of mitochondrial markers directly correlates with poor
clinical outcome in ovarian (27) and breast cancer patients
(28).
Finally, as early as 2002, it was first reported that doxycycline
effectively reduces bone metastasis, by up to ∼60–80%, in an
in vivo pre-clinical murine model of human breast cancer (29).
Mechanistically, these findings may be due to the ability of
doxycycline to eradicate CSCs, although this hypothesis was not
tested at that time.
RESULTS
Description of the Breast Cancer Patient
Population
A summary diagram highlighting the organizational structure
of this doxycycline “window-of-opportunity” study (Phase II) is
shown in Figure 1.
A total of 15 female patients with early breast cancer
participated in the current pilot study. Nine patients received
doxycycline (200mg per day) for a 14-day period, while
six patients remained untreated. A summary of the clinical
characteristics of the patient population are shown in Table 1.
Briefly, in the doxycycline treatment group, patient age at
diagnosis ranged between 42 and 65 years of age, tumor size
was between 10 and 30mm, and 6 out of 9 patients were grade
2. In addition, 7 out of 9 patients were ER(+), with 6 being of
the luminal A sub-type and one of the luminal B sub-type. In
addition, two patients were of the HER2(+) sub-type.
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FIGURE 1 | Schematic diagram summarizing the organizational structure of
the Doxycycline clinical pilot study. Note that this Phase II
“Window-of-Opportunity” format provides an excellent clinical mechanism for
evaluating FDA-approved antibiotics, as potential candidates for drug
repurposing.
TABLE 1 | Clinical characteristics of the patient population.
Treated patients Age Tumor size (mm) Grade Molecular subtype
Case 1 42 12 2 Luminal A
Case 2 57 15 3 HER2pos
Case 4 65 23 3 HER2pos
Case 5 52 10 2 Luminal A
Case 7 46 12 2 Luminal A
Case 8 46 27 2 Luminal B
Case 13 50 10 2 Luminal A
Case 14 52 13 1 Luminal A
Case 15 44 30 2 Luminal A
Untreated patients
Case 3 71 25 3 Luminal B
Case 6 50 15 2 Luminal A
Case 9 51 12 2 Luminal A
Case 10 48 25 3 Luminal B
Case 11 41 21 2 Luminal A
Case 12 69 16 3 Luminal/HER2pos
In the untreated control group, patient age ranged between
41 and 71 years of age, and tumor size was between
12 to 25mm; 3 patients were grade 2 and 3 patients
were grade 3. All 6 patients were ER(+), with 3 of the
luminal A sub-type, 2 of the luminal B sub-type and
one showing characteristics of both luminal/HER2(+) sub-
types.
Thus, both groups were well-matched for age and clinical
characteristics.
Status of Biomarkers in Tumor Tissue
Sections, Before and After Receiving Oral
Doxycycline
We quantitatively assessed the expression of several diverse
biomarkers in paraffin-embedded tumor tissue sections. These
included markers of “stemness” (CD44, ALDH1), mitochondria
(TOMM20), cell proliferation (Ki67, p27), apoptosis (cleaved
caspase-3), and neo-angiogenesis (CD31).
Figure 2 highlights that most of the tumor markers remained
unchanged before and after receiving oral doxycycline, with the
exception of CD44—a marker of “stemness.” More specifically,
CD44 was reduced on average by ∼40% (p < 0.005), in
the patients examined. Note that 4 out of 9 patients showed
reductions of 50% or greater in CD44.
The results of multi-variate analysis are included as
Supplemental Information and demonstrated that CD44
reductions remained significant (ANOVA; p < 0.0007) and
were independent of all the other variables tested [including
histological grade (1, 2, 3), tumor diameter type (small, large)
and molecular subtype] (see Tables S1–S15). In contrast, cleaved
caspase-3 levels appeared to be elevated after receiving oral
doxycycline; however, this did not reach statistical significance,
except in the case of low histological grade (See Table S4).
Figure 3 shows a waterfall plot of CD44 expression in the
9 individual breast cancer patients. Remarkably, CD44 levels
were reduced between 17.65 and 66.67%, in 8 out of 9 patients
treated with doxycycline. Representative images of this reduction
in CD44 immuno-staining are illustrated in Figure 4 for two
patients. In contrast, only one patient showed a rise in CD44, by
15%. Overall, this represents a positive response rate approaching
90%. It is worth noting that the levels of cleaved caspase-3 were
most strikingly elevated in the two patients (Cases 8 & 14) that
showed the largest reductions in CD44 expression (Figure 5).
Therefore, a certain threshold level may need to be reached to
augment the activation of caspase-3.
The two patients of the HER2(+) sub-type, also showed
positivity for another stem cell marker, namely ALDH1.
Interestingly, ALDH1 levels were reduced by nearly 60% in one
patient (Case 2), while ALDH1 levels were reduced by ∼90%
in the other patient (Case 4) (Figure 6), all in response to
doxycycline. These results are also consistent with reductions in
CD44; in these same two HER2(+) patients, CD44 levels were
reduced by nearly 40% (Case 2) and 60% (Case 4), respectively
(Figure 3).
Status of Biomarkers in Tumor Tissue
Sections From the Untreated Control
Group, Before and After Surgery
In contrast to our results with the doxycycline treated patient
population, patients in the untreated control group did not
show any statistically significant changes in the expression of
CD44, when tumor tissue sections were compared before and
after surgery (Figure S1). The results of multi-variate analysis
are included as Supplemental Information (Tables S11–S15) and
showed that CD44 remained unchanged (seeTable S13; ANOVA;
P < 0.7707).
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FIGURE 2 | Effects of doxycycline administration on the expression of six different classes of biomarkers in early breast cancer patients (Ki67, Cleaved Caspase-3,
CD31, CD44, p27, and TOMM20). Note that only CD44 levels were significantly reduced on average by nearly 40% (***; p < 0.005), while the levels of other markers
remained unchanged. The results of multi-variate analysis are included as Supplemental Information and show that CD44 remained significant (ANOVA; p < 0.0007)
and was independent of all the other variables tested [histological grade (1, 2, 3), diameter type (small, large) and molecular subtype] (see Tables S1–S15).
Therefore, surgery itself was not sufficient to significantly
change the expression levels of the tumor markers examined,
including CD44.
DISCUSSION
Here, we conducted a clinical pilot study with doxycycline, to
assess its effects in early breast cancer patients. Importantly, most
biomarkers tested remained unchanged, with the exception of
CD44, which was reduced on average by nearly 40%, in a period
of only two weeks of treatment. Analysis of waterfall plot data
revealed that in 8 out of 9 patients treated with doxycycline, CD44
levels were reduced between 17.65 and 66.67%. In contrast, only
one patient showed a rise in CD44, by 15%. Two patients of
the HER2(+) sub-type, also showed positivity for another stem
cell marker, namely ALDH1. In these HER2(+) patients, ALDH1
levels were reduced by nearly 60% in one patient, while ALDH1
levels were reduced by 90% in the other patient, in response to
doxycycline. Thus, oral doxycycline treatment effectively reduced
the expression of two CSC markers, in early breast cancer
patients.
Our current in vivo results are consistent with recent findings
in MCF7 and MDA-MB-468 cells, two human breast cancer
cell lines in culture, which showed significant reductions in the
CD44(+)/CD24(-/low) CSC population, after treatment with
doxycycline (17). In addition, the expression levels of other
“stemness” markers (Oct4, Sox2, Nanog and CD44) were also
reduced by >50%, in response to doxycycline, as assessed by
mRNA levels and independently confirmed by immuno-blot
analysis (17).
Similarly, doxycycline has been shown to reduce ALDH(+)
breast CSCs in HER2(+) and triple-negative human breast
cancer cell lines in vitro (18). As such, doxycycline may be useful
for targeting both the CD44(+) and ALDH(+) sub-populations
of human breast CSCs (17, 18).
The levels of cleaved caspase-3 appeared to be elevated
after treatment with Doxycycline; however, this did not reach
statistical significance in all the tumor grades. Nevertheless,
Doxycycline has been shown to induce apoptosis in human breast
cancer cell lines in vitro (17).
CONCLUSIONS
Pre-operative treatment with oral doxycycline (200mg per
day) for 2 weeks is sufficient to reduce both CD44 and
ALDH1 expression in tumor tissue from early breast cancer
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FIGURE 3 | Effect of doxycycline administration on the expression of CD44 in
early breast cancer patients: Waterfall plot. Note that CD44 levels were
reduced between 17.65 and 66.67%, in 8 out of 9 patients treated. In
contrast, only one patient showed a rise in CD44, by 15%. Overall, this
represents a positive response rate of nearly 90%. Also, note that 4 out of 9
patients showed reductions of 50% or greater in CD44.
patients. However, additional clinical studies (with larger patient
numbers) will be required to further validate these promising
clinical pilot studies.
MATERIALS AND METHODS
Trial Construction, Ethical Review and EU
Clinical Trial Registration
A Phase II clinical trial (pre-operative “window” study; Figure 1)
for the use of oral doxycycline in early breast cancer patients
was submitted, reviewed, and approved by the local and national
ethics committees at the Pisa University Hospital and the
Italian Ministry of Health (Rome, Italy). All patients underwent
informed written consent, prior to their inclusion in the
study. Doxycycline was administered during the “window-of-
opportunity,” after diagnosis and exactly 14 days before the date
of surgery, while the patient was waiting for tumor excision
at surgery. The acronym for the trial is ABC (Antibiotics for
Breast Cancer) and the EudraCT registration number is 2016-
000871-26. EudraCT is the European Clinical Trials Database
(European Union Drug Regulating Authorities Clinical Trials).
The full title of the study is: “A Phase II Open-Label Randomized
Controlled Pre-Surgical Feasibility Study of Doxycycline in Early
Breast Cancer.” The objective and primary goal of the trial
is: To determine whether short-term (2-weeks) pre-operative
treatment with oral doxycycline of stage I-to-III early breast
cancer patients results in inhibition of tumor proliferation
markers, as determined by a reduction in tumor Ki67 from
baseline (pre-treatment) to post-treatment (at time of surgical
excision). Doxycycline (Bassado-brand) was administered orally,
100-mg twice a day for a total of 200-mg per day, for
a period of 14-days. During this period, the control group
received no medical therapy (i.e., standard of care: waiting for
surgery). Information about study subjects is kept confidential
and managed according to the requirements of the EU and
Italian regulations. All of our breast cancer cases were NST (No
Special Type, invasive carcinomas), previously known as “ductal”
carcinomas.
Plasma Doxycycline Levels
Doxycycline oral intake was validated by measuring the
concentrations in plasma samples, obtained immediately prior
to surgery [mean +/– SD, 0.76 ± 0.41 mg/L, range 0.25–1.57
mg/L]. Doxycycline levels were determined bymass spectrometry
analysis. This precise monitoring confirmed the compliance of
patients to the planned treatment regimen, proposed to them at
the time of enrollment.
Immuno-Staining Reagents
Antibodies for immuno-staining were purchased from
commercial sources, as briefly summarized in Table S16.
Immuno-Staining and Quantitation
Tumor expression of Ki67, p27, cleaved caspase 3, CD31, CSC
markers (CD44, ALDH1), and mitochondria (TOMM20) was
performed on formalin-fixed paraffin-embedded tumor tissues.
Tissue sections (4 micron) were de-paraffinized with xylene
and rehydrated through a graded alcohol series. After rinsing
with phosphate buffer saline (PBS) sample were immersed in
sodium citrate buffer (pH 6) for p27 and cleaved caspase 3 and
in UNMASKER buffer (pH 7,8) for CD44, TOMM20, ADLH1,
and heated in a microwave oven at 100◦C. The endogenous
peroxidase was blocked by 10min incubation in 3% H2O2.
After blocking with normal goat serum for 10min at room
temperature, the slides were further incubated overnight at
4◦C with the following primary antibodies: mouse anti CD44
(1:1000, clone 156-3C11), mouse anti-ALDH1A1, (1:500, clone
703410), rabbit anti cleaved caspase 3 (Asp175; 1:150), rabbit
anti-p27 (1:250) and mouse anti TOMM20 (1:250, clone F-10). A
biotin conjugated goat derived secondary antibody was applied
followed by the enzyme-labeled streptavidin and substrate
chromogen (Rabbit/Mouse specific HRP/DAB-ABC detection
IHC kit, Abcam). Slides were counterstained with hematoxylin.
The immunostaining for Ki67 (ready to use, clone MIB-1,
Dako) and CD31 (ready to use, clone JC70, Ventana Medical
Systems) instead was performed in an automated immunostainer
(BenchMark Ultra, Ventana Medical Systems). Staining intensity
and percentage of positive tumor cells was measured. Ki67 is a
nuclear marker expressed in all phases of the cell cycle except
G0. The “Ki67 index” (percentage of nuclei showing nuclear
immuno-reactivity of any intensity) was determined as per
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FIGURE 4 | Effect of doxycycline administration on the expression of CD44 in early breast cancer patients: Representative images are shown. Note that treatment
with doxycycline reduces the expression of CD44, as seen by immuno-histochemical staining. Representative images from two case are shown. Magnification, 40X.
FIGURE 5 | Effect of doxycycline administration on the levels of cleaved
caspase 3 in early breast cancer patients. Note that the levels of cleaved
caspase 3 showed the largest increases in two patients, which demonstrated
the highest reductions in CD44 levels (Cases 8 and14); compare with
Figure 3. In addition, the levels of cleaved caspase 3 were increased in 4 out
of 9 patients studied (∼44 %).
FIGURE 6 | Effect of doxycycline administration on the expression of ALDH1
in HER2(+) early breast cancer patients. The two patients of the HER2(+)
sub-type, also showed positivity for another stem cell marker, namely ALDH1.
Note that ALDH1 levels were reduced by nearly 60% in one patient (Case 2),
while ALDH1 levels were reduced by 90% in the other patient (Case 4), in
response to doxycycline.
routine protocols. p27 (nuclear staining) is a cell cycle inhibitor
that negatively correlates with Ki67. Caspase-3 (cytoplasmic
and/or nuclear staining) is synthesized as an inactive pro-enzyme
which is activated by cleavage in cells undergoing apoptosis.
CD31 (membranous staining) is expressed by endothelial cells
and is used as a marker of angiogenesis. CD44 (membranous
staining: complete or incomplete, of any intensity) and ALDH1
(cytoplasmic staining) are well-established markers that are
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elevated in cells with “stem-like” characteristics. TOMM20
(cytoplasmic staining), a central component of the receptor
complex responsible for the recognition and translocation of
cytosolically synthesized mitochondrial preproteins, is used as a
marker of mitochondria. Staining percentage of positive tumor
cells was measured independently by two blinded-pathologists.
Discrepancies in interpretation or scoring (<5% of cases)
were resolved by consensus conference at a double-headed
microscope. All changes in tumor markers were analyzed as
a percentage (pre-post/pre x 100) and an absolute (pre-post)
change from baseline.
Statistical Analysis
The values of themarkers before the treatment were our reference
(100%), and all the other values measured after the treatment
are presented as a post/pre ratio, to point out any increases or
decreases from the reference value. The values in the graphs are
represented by the average value of each endpoint, with relative
standard error of the mean (SEM). The significant differences
were assessed with MedCalc 12 (unpaired t-test). Values of
p <0.05 were considered statistically significant. Multi-variate
analysis with ANOVA was also carried out and the results of
this analysis are included as Supplementary Information (see
Tables S1–S15).
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